MarketCap
Facebook
X
Telegram
Aytu BioScience Income Statement 2025-2005 | AYTU
Brief overview of financial results at Aytu BioScience
The figures are compared over a five-year interval. The revenue attributed to Aytu BioScience moved from 27.6 million dollars to 66.4 million dollars between the two endpoints. The five-year change reached +140.2%, while CAGR stood at 19.2%. Revenue followed a strong upward trend without signs of stagnation.
The gross result shifted from 20.1 million dollars to 45.8 million dollars, or +128.3%. The cost base moved against the top-line trend and weighed on the gross result. Comparing the endpoints gives gross margins of 72.7% and 69%. The business retained less gross profit from each unit of revenue.
EBITDA was −$16.4 million at the beginning and −$2.5 million at the end of the period (+85.1%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from −59.5% to −3.7%. A wider margin confirms stronger operating efficiency.
The final result was −$13.6 million initially and −$13.6 million in the final year. The loss reduction is constructive, but the recovery is incomplete.
Overall conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The constructive conclusion rests on higher operating efficiency, a larger revenue base and stable net income. The main areas of concern are a narrow EBITDA buffer and weaker gross profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
15.8 M | 15.8 M | 10.5 M | 279 K | 16.7 M | 61.9 M | 12.5 M | 3.73 M | 5.5 M | 14.6 M | 5.42 M | 1.05 M | 937 K | 3.28 M | 1.31 M | - | - | - | - | - | - |
Shares |
6.28 M | 5.54 M | 3.34 M | 1.47 M | 16.7 M | 4.52 M | 779 K | 66.6 K | 2.33 K | 935 | 297 | 9 | 8 | 8 | 8 | - | - | - | - | - | - |
Historical Prices |
2.51 | 2.85 | 3.13 | 0.19 | 1.26 | 7.67 | 5.3 | 11.7 | 128 | 3.76 K | 30.2 K | 146 K | 205 K | 410 K | 451 K | 4.45 M | 5.97 M | - | - | - | - |
Net Income |
-13.6 M | -15.8 M | -17.1 M | -109 M | -58.3 M | -13.6 M | -27.1 M | -10.2 M | -22.5 M | -28.2 M | -7.72 M | -5.58 M | -57.3 K | -59.7 K | -137 K | -60.3 K | -58.9 K | -57.2 K | -49 K | -70.4 K | -18.7 K |
Revenue |
66.4 M | 65.2 M | 107 M | 96.7 M | 65.6 M | 27.6 M | 7.32 M | 3.66 M | 3.22 M | 2.56 M | 262 K | 58.9 K | 1.75 K | 1.75 K | - | - | - | - | - | - | - |
Cost of Revenue |
20.6 M | 16.1 M | 40.8 M | 44.4 M | 36.4 M | 8.28 M | 2.2 M | 2.05 M | 1.42 M | 957 K | 88.1 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
45.8 M | 49.1 M | 66.6 M | 52.3 M | 29.2 M | 20.1 M | 5.12 M | 1.61 M | 1.8 M | 1.61 M | 174 K | 58.9 K | - | 1.75 K | - | - | - | - | - | - | - |
Operating Income |
-7.83 M | -1.59 M | -17.1 M | -110 M | -58.9 M | -21.1 M | -16.8 M | -19.7 M | -20.1 M | -21.7 M | -7.63 M | -6.35 M | -52.4 K | -56.4 K | -134 K | - | - | - | - | - | - |
Interest Expense |
-512 K | 870 K | 184 K | -757 K | -2.05 M | 2.61 M | 536 K | 749 K | 2.53 M | 5.49 M | 115 K | -45.6 K | 4.9 K | 3.32 K | 3.18 K | - | - | - | - | - | - |
EBITDA |
-2.45 M | 6.68 M | -8.25 M | -99.8 M | -49.7 M | -16.4 M | -14.7 M | -16.3 M | -17.2 M | -13.5 M | -7.51 M | -6.25 M | -47.5 K | -50.2 K | -127 K | - | - | - | - | - | - |
Operating Expenses |
53.7 M | 50.6 M | 83.7 M | 162 M | 88.1 M | 41 M | 22 M | 19.5 M | 20.7 M | 15.8 M | 7.81 M | 6.41 M | 54.2 K | 58.1 K | 134 K | - | - | - | - | - | - |
General and Administrative Expenses |
17.4 M | 20 M | 28.6 M | 31.2 M | 25.5 M | 34.8 M | 19.2 M | 17.7 M | 17.6 M | 8.83 M | 4.38 M | 2.35 M | 48 K | 58.1 K | 129 K | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Aytu BioScience
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10.5 M | 10 M | 9.44 M | 10 M | 9.44 M | 8.98 M | 6.13 M | 6.13 M | 6.07 M | 5.97 M | 5.53 M | 5.52 M | 5.48 M | 5.52 M | 3.73 M | 3.11 M | 2.52 M | 1.93 M | 1.48 M | 1.32 M | 25.6 M | 1.3 M | 18.1 M | 13.3 M | 12.2 M | 12.7 M | 3.53 M | 1.75 M | 15.3 M | 17.5 M | 15.3 M | 6.48 M | 1.76 M | 6.48 M | 1.76 M | 206 K | 121 K | 4.11 M | 2.42 M | 393 K | 245 K | 7.85 M | 4.9 M | 1.19 M | 1.19 M | 14.3 M | 14.3 M | 7.9 M | 7.9 M | 7.9 M | 44.7 M | 4.92 M | 4.9 M | 4.86 M | 4.9 M | 4.89 M | 4.86 M | 4.86 M | 4.73 M | 4.77 M | 4.73 M | 4.73 M | 4.73 M |
Net Income |
-5.62 M | -10.6 M | 1.96 M | -10.6 M | 1.96 M | - | 3.99 M | 788 K | 1.47 M | - | -2.89 M | -220 K | -8.12 M | - | -7.2 M | -6.69 M | -701 K | -7.39 M | -53.3 M | -11.5 M | -27.9 M | -39.4 M | -25.5 M | -9.52 M | -9.53 M | -9.53 M | -4.31 M | -214 K | -214 K | -214 K | -4.93 M | -4.66 M | -4.66 M | -4.66 M | -3.45 M | -3.67 M | -4.25 M | -3.67 M | -4.25 M | -4.82 M | -5.72 M | -4.82 M | -5.72 M | -3.33 M | -2.28 M | -3.33 M | -2.28 M | -1.62 M | -2.11 M | -11.8 K | -15.8 K | -16.5 K | -57.3 K | -57.3 K | -16.5 K | -19.9 K | -11.9 K | -11.9 K | -19.9 K | -19.7 K | -137 K | -137 K | -19.7 K |
Revenue |
12.4 M | 15.2 M | 13.9 M | 15.2 M | 13.9 M | - | 18.5 M | 16.2 M | 16.6 M | - | 14 M | 18.7 M | 17.8 M | - | 22.7 M | 26.3 M | 27.7 M | 53.9 M | 24.2 M | 23.1 M | 21.9 M | 45 M | 13.5 M | 15.1 M | 13.5 M | 29 M | 8.16 M | 3.18 M | 1.44 M | 3.18 M | 1.44 M | 1.8 M | 1.43 M | 1.8 M | 607 K | 1.05 M | 1.08 M | 2.13 M | 894 K | 794 K | 698 K | 794 K | 698 K | 448 K | 466 K | 448 K | 466 K | 7 K | 6 K | - | 12.5 K | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
4.81 M | 5.54 M | 4.7 M | 5.54 M | 4.7 M | - | 5.65 M | 5.44 M | 4.59 M | - | 3.66 M | 4.14 M | 4.78 M | - | 9.99 M | 8.99 M | 9.62 M | 18.6 M | 11.5 M | 10.8 M | 9.44 M | 20.3 M | 13.9 M | 6.25 M | 4.06 M | 6 M | 3.82 M | 606 K | 376 K | 606 K | 376 K | 525 K | 411 K | 525 K | 411 K | 385 K | 287 K | 385 K | 287 K | 551 K | 192 K | 551 K | 192 K | 244 K | 37.3 K | 244 K | 37.3 K | - | 225 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
7.6 M | 9.62 M | 9.19 M | 9.62 M | 9.19 M | - | 12.8 M | 10.8 M | 12 M | - | 10.4 M | 14.6 M | 13 M | - | 12.7 M | 17.3 M | 18 M | 35.3 M | 12.7 M | 12.3 M | 12.5 M | 24.8 M | -452 K | 8.9 M | 9.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-4.06 M | -1.97 M | -1.5 M | -1.97 M | -1.5 M | - | 2.42 M | -1.7 M | -930 K | - | -1.6 M | 3.15 M | -867 K | - | -8.56 M | -6.87 M | -1.81 M | -8.45 M | -53.4 M | -11.3 M | -27.7 M | -39 M | -25.7 M | -5.58 M | -3.56 M | -5.58 M | -3.56 M | -4.97 M | -4.74 M | -4.97 M | -4.74 M | -4.55 M | -3.42 M | -4.55 M | -3.42 M | -3.99 M | -4.36 M | -3.99 M | -4.36 M | -4.2 M | -5.97 M | -4.2 M | -5.97 M | -3.01 M | -2.16 M | -3.01 M | -2.16 M | -1.58 M | -2.09 M | -11.1 K | -15.3 K | -15 K | -43.3 K | -12 K | -15 K | -18.8 K | -11.1 K | -11.1 K | -18.8 K | -18.9 K | -62.9 K | -20 K | -18.9 K |
Interest Expense |
149 K | 190 K | 201 K | 190 K | 201 K | - | 36 K | 140 K | 542 K | - | 70 K | 96 K | 584 K | - | -1.22 M | -1.23 M | -1.08 M | -2.54 M | -32 K | -257 K | -40 K | -516 K | -425 K | -379 K | 752 K | - | 539 K | 447 K | 195 K | 642 K | 195 K | 128 K | 76.6 K | 128 K | 76.6 K | 197 K | 189 K | 197 K | 189 K | 388 K | 415 K | 388 K | 415 K | 240 K | 113 K | 240 K | 113 K | 37.5 K | 37.3 K | 692 | 463 | 1.5 K | 3.44 K | 1.31 K | 1.5 K | 1.03 K | 855 | 855 | 1.03 K | 791 | 2.38 K | 694 | -791 |
EBITDA |
-1.26 M | -282 K | -701 K | -1.87 M | -701 K | - | 2.52 M | -1.6 M | 404 K | - | -1.4 M | 3.45 M | 57 K | - | -6.72 M | -5.02 M | 493 K | -3.94 M | -52.9 M | -10.9 M | -25 M | -33.6 M | -25.6 M | -5.56 M | -1.52 M | -1.56 M | -1.46 M | -4.95 M | -3.87 M | -2.81 M | -3.87 M | -4.53 M | -2.86 M | -3.32 M | -2.86 M | -3.66 M | -3.7 M | -2.68 M | -3.7 M | -4.17 M | -5.14 M | -2.48 M | -5.14 M | -3 M | -2.03 M | -2.77 M | -2.03 M | -1.58 M | -2.07 M | -8.74 K | -15.3 K | -13.8 K | -39.6 K | -9.42 K | -13.8 K | -17.5 K | -6.3 K | -7.76 K | -17.5 K | -17.2 K | -57.8 K | -16.7 K | -17.2 K |
Operating Expenses |
11.7 M | 11.6 M | 10.7 M | 11.6 M | 10.7 M | - | 10.4 M | 12.5 M | 12.9 M | - | 12 M | 11.5 M | 13.9 M | - | 21.3 M | 24.2 M | 19.8 M | 43.8 M | 66.1 M | 23.6 M | 40.2 M | 63.7 M | 25.2 M | 14.5 M | 13 M | - | 17.1 M | 8.14 M | 6.18 M | 14.3 M | 6.18 M | 6.35 M | 4.85 M | 6.35 M | 4.85 M | 5.05 M | 5.43 M | 5.05 M | 5.43 M | 4.99 M | 6.66 M | 4.99 M | 6.66 M | 3.48 M | 2.65 M | 3.48 M | 1.83 M | 1.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.97 M | 5.07 M | 4.92 M | 5.07 M | 4.92 M | - | 4.11 M | 4.45 M | 5.12 M | - | 4.83 M | 4.8 M | 6.3 M | - | 7.18 M | 8.02 M | 7.32 M | 15.3 M | 7.62 M | 7.95 M | 8.22 M | 16.2 M | 6 M | 5.58 M | 5.42 M | 24.3 M | 9.19 M | 6.52 M | 5.15 M | 6.52 M | 5.15 M | 5.05 M | 3.58 M | 5.05 M | 3.58 M | 4.55 M | 4.62 M | 4.55 M | 4.62 M | 3.64 M | 5.7 M | 3.64 M | 5.7 M | 1.69 M | 1.56 M | 1.77 M | 1.09 M | 5.27 K | 1.72 M | 5.12 K | 737 K | 6.62 K | 24.2 K | 9.33 K | 6.62 K | 6.78 K | 5.83 K | 5.83 K | 6.78 K | 8.79 K | 40.5 K | 14.2 K | 8.79 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Aytu BioScience (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
